These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29271107)

  • 1. Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.
    Coppa A; Nicolussi A; D'Inzeo S; Capalbo C; Belardinilli F; Colicchia V; Petroni M; Zani M; Ferraro S; Rinaldi C; Buffone A; Bartolazzi A; Screpanti I; Ottini L; Giannini G
    Cancer Med; 2018 Jan; 7(1):46-55. PubMed ID: 29271107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
    Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
    JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of BRCA1/2 testing in high-risk breast/ovarian/male breast cancer families: little contribution of comprehensive RNA/NGS panel testing.
    Byers H; Wallis Y; van Veen EM; Lalloo F; Reay K; Smith P; Wallace AJ; Bowers N; Newman WG; Evans DG
    Eur J Hum Genet; 2016 Nov; 24(11):1591-1597. PubMed ID: 27273131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
    Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
    J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
    Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
    JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    Cragun D; Weidner A; Tezak A; Clouse K; Pal T
    Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
    Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
    Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
    Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
    Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond BRCA: A Case Series Examining the Advent of Multigene Panel Testing.
    Reap L; Ahsan S; Saleh M
    Clin Breast Cancer; 2018 Aug; 18(4):e431-e439. PubMed ID: 29739691
    [No Abstract]   [Full Text] [Related]  

  • 17. Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients.
    Silva FC; Lisboa BC; Figueiredo MC; Torrezan GT; Santos EM; Krepischi AC; Rossi BM; Achatz MI; Carraro DM
    BMC Med Genet; 2014 May; 15():55. PubMed ID: 24884479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1 and BRCA2 Germline Mutation Analysis in Hereditary Breast/Ovarian Cancer Families from the Aures Region (Eastern Algeria): First Report.
    Mehemmai C; Cherbal F; Hamdi Y; Guedioura A; Benbrahim W; Bakour R; Abdelhak S
    Pathol Oncol Res; 2020 Apr; 26(2):715-726. PubMed ID: 30715675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.